GALDERMA GRP AG
162,05€
-0,05 (-0,03%)
16.09.2026, 14:31:23 Uhr
WKN: A407X6 ISIN: CH1335392721 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® +61,01 +0,24% 25.463,29
- MDAX ® +78,59 +0,25% 31.135,75
- TecDAX ® +15,87 +0,40% 3.976,62
- E-STOXX 50 ® -23,88 -0,38% 6.236,50
- NASDAQ 100 -189,32 -0,65% 28.937,84
- HANG SENG +41,16 +0,17% 24.713,78
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 162,10€ | -0,03% |
| 1 Woche | 171,90€ | -5,70% |
| 1 Monat | 184,45€ | -12,12% |
| 6 Monate | 157,65€ | +2,82% |
| Lfd. Jahr (YTD) | -- | -- |
| 1 Jahr | -- | -- |
| 3 Jahre | -- | -- |
| 5 Jahre | -- | -- |
Kursdaten
| Kurs | 162,05€ |
| Schluss Vortag | 162,10€ |
| Eröffnung | 162,50€ |
| Geld | 161,40€ |
| Brief | 161,60€ |
| Tages-Hoch | 162,70€ |
| Tages-Tief | 160,60€ |
| 52 Wochen-Hoch | 204,00€ |
| 52 Wochen-Tief | 149,00€ |
| Allzeit-Hoch | 204,00€ |
| Allzeit-Tief | 149,00€ |
Nachrichten
- BUSINESS WIRE: Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing - 16.09.2026, 07:00:01 Uhr
- BUSINESS WIRE: Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping - 11.08.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year - 23.07.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region - 20.07.2026, 07:00:03 Uhr
- BUSINESS WIRE: Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns - 07.07.2026, 07:00:06 Uhr
- BUSINESS WIRE: Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States - 01.07.2026, 07:00:07 Uhr
- BUSINESS WIRE: Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments - 11.06.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch - 22.05.2026, 18:25:04 Uhr
- BUSINESS WIRE: Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency - 23.04.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Shareholders Approve All Annual General Meeting Proposals - 22.04.2026, 17:45:02 Uhr
